John Lawler

Dr. John Lawler


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2024 in Nature
Verified
Journal Article
Open access
PDF file
Christopher MasonChristopher Mason
Christopher Mason
JGJames Lauer Green
James Lauer Green
KONSTANTINOS ADAMOPOULOSKONSTANTINOS ADAMOPOULOS
KONSTANTINOS ADAMOPOULOS
EAEvan E. Afshin
Evan E. Afshin
JBJordan J. Baechle
Jordan J. Baechle
ABAfshin Beheshti
Afshin Beheshti
The recent acceleration of commercial, private, and multi-national spaceflight has created an unprecedented level of activity in low Earth orbit (LEO), concomitant with the highest-ever number of crewed missions entering space and preparations for exploration-class (>1 year) missions. Such rapid advancement into space from many new companies, countries, and space-related entities has enabled a“Second Space Age.” This new era is also poised to leverage, for the first time, modern tools and methods of molecular biology and precision medicine, thus enabling precision aerospace medicine for the crews. The applications of these biomedical technologies and algorithms are diverse, encompassing multi-omic, single-cell, and spatial biology tools to investigate human and microbial responses to spaceflight. Additionally, they extend to the development of new imaging techniques, real-time cognitive assessments, physiological monitoring, and personalized risk profiles tailored for astronauts. Furthermore, these technologies enable advancements in pharmacogenomics (PGx), as well as the identification of novel spaceflight biomarkers and the development of corresponding countermeasures. In this review, we highlight some of the recent biomedical research from the National Aeronautics and Space Administration (NASA), Japan Aerospace Exploration Agency (JAXA), European Space Agency (ESA), and other space agencies, and also detail the commercial spaceflight sector’s (e.g. SpaceX, Blue Origin, Axiom, Sierra Space) entrance into aerospace medicine and space biology, the first aerospace medicine biobank, and the myriad upcoming missions that will utilize these tools to ensure a permanent human presence beyond LEO, venturing out to other planets and moons.

14 September 2016 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
JLJohn Lawler
John Lawler
DRDinah A. Rodriguez
Dinah A. Rodriguez
JHJeff Hord
Jeff Hord

1 October 2016 in Experimental Gerontology
Verified
Journal Article
Closed access
JHJeff Hord
Jeff Hord
RBRachel Botchlett
Rachel Botchlett
JLJohn Lawler
John Lawler

1 May 2019 in Nutrition Research
Verified
Journal Article
Closed access
JLJohn Lawler
John Lawler
EGErika L. Garcia-Villatoro
Erika L. Garcia-Villatoro
Vinicius GuzzoniVinicius Guzzoni
Vinicius Guzzoni
JHJeff M. Hord
Jeff M. Hord
RBRachel Botchlett
Rachel Botchlett
STSusanne Talcott
Susanne Talcott

Verified
Journal Article
Open access
PDF file
JLJohn Lawler
John Lawler
JHJeff Hord
Jeff Hord
PRPatrick Ryan
Patrick Ryan
DHDylan Holly
Dylan Holly
MGMariana Janini Gomes
Mariana Janini Gomes
KKKhaled Kamal
Khaled Kamal
Insufficient stress response and elevated oxidative stress can contribute to skeletal muscle atrophy during mechanical unloading (e.g., spaceflight and bedrest). Perturbations in heat shock proteins (e.g., HSP70), antioxidant enzymes, and sarcolemmal neuronal nitric oxidase synthase (nNOS) have been linked to unloading-induced atrophy. We recently discovered that the sarcolemmal NADPH oxidase-2 complex (Nox2) is elevated during unloading, downstream of angiotensin II receptor 1, and concomitant with atrophy. Here, we hypothesized that peptidyl inhibition of Nox2 would attenuate disruption of HSP70, MnSOD, and sarcolemmal nNOS during unloading, and thus muscle fiber atrophy. F344 rats were divided into control (CON), hindlimb unloaded (HU), and hindlimb unloaded +7.5 mg/kg/day gp91ds-tat (HUG) groups. Unloading-induced elevation of the Nox2 subunit p67phox-positive staining was mitigated by gp91ds-tat. HSP70 protein abundance was significantly lower in HU muscles, but not HUG. MnSOD decreased with unloading; however, MnSOD was not rescued by gp91ds-tat. In contrast, Nox2 inhibition protected against unloading suppression of the antioxidant transcription factor Nrf2. nNOS bioactivity was reduced by HU, an effect abrogated by Nox2 inhibition. Unloading-induced soleus fiber atrophy was significantly attenuated by gp91ds-tat. These data establish a causal role for Nox2 in unloading-induced muscle atrophy, linked to preservation of HSP70, Nrf2, and sarcolemmal nNOS.

28 February 2018 in Experimental Physiology
Verified
Journal Article
Closed access
PDF file
JKJ. Matthew Kuczmarski
J. Matthew Kuczmarski
JHJeff M. Hord
Jeff M. Hord
YLYang Lee
Yang Lee
Vinicius GuzzoniVinicius Guzzoni
Vinicius Guzzoni
DRDinah Rodriguez
Dinah Rodriguez
JLJohn Lawler
John Lawler